

AstraZeneca
1Q 2014 Results



Cautionary statement regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This presentation contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.

The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing exclusivity or trade marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; and the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation.

Nothing in this presentation should be construed as a profit forecast.

Agenda

Pascal Soriot
First quarter 2014 overview

Briggs Morrison
Pipeline update

Marc Dunoyer
First quarter 2014 financial performance

Pascal Soriot
Closing remarks

1Q 2014: Continued momentum

Pascal Soriot, Chief Executive Officer

1Q 2014: Highlights

Returning to growth

- **1Q revenue up 3% at CER**
- **Good progression of the 5 growth platforms**
- ***Farxiga* launch encouraging in the US**

Achieving scientific leadership

- **Olaparib Priority Review accepted by FDA**
- **AZD9291 granted Breakthrough Therapy designation by FDA**
- **4 Phase III investment decisions**

1Q 2014: Positive revenue growth

	1Q 14 $m	CER growth %
Global Revenue	**6,416**	**3**
US	2,513	3
Europe	1,637	(4)
Emerging Markets	1,421	11
China	584	22
Japan	537	13
Core EPS	**$1.17**	**(11)**

Continued good progress in 1Q on our strategic priorities

1

Achieve scientific leadership

2

Return to growth

3

Be a great place to work

Growth platform revenue up 15% to $3.3bn

	1Q 14 $m	CER growth %
Growth drivers	**3,297**	**15***
Brilinta	**99**	**94**
Diabetes	**347**	**106***
Respiratory	**1,271**	**12**
Emerging Markets	**1,421**	**11**
Japan	**537**	**13**

*Diabetes growth rate includes 2 months of revenue in 1Q14 of assets owned by BMS in 1Q13

Brilinta: Continued good progress in Europe and International



- 1Q *Brilinta* revenue up 94% to $99m
- Leadership position maintained in several European markets
- Awaiting DOJ resolution in the US

Note: Growth rate at CER

Brilinta: Market share uptake in Europe









Note: Month 1 = month of 1st external sales data for product (does not reflect commercial launch timing)

Brilinta: US performance



Diabetes: Growing the franchise



- Revenue growing to $347m
- *Farxiga* US launch progressing well
- *Onglyza* US share 0.7% decline 1Q
- *Bydureon* US share growing
- BMS integration on track

Diabetes: 2 out of 5 *Farxiga* trialists new to SGLT-2 class



Diabetes: *Farxiga* uptake exceeding recent NIAD* launches



*NIAD: non-insulin anti-diabetics

Respiratory: *Symbicort* up 13%



- 1Q *Symbicort* revenue up 13% to $928m
- *Symbicort* new to combination market share up 3.7 points in US
- Share growth in US, Japan, China and many International markets

Note: Growth rate at CER

Respiratory: Strong *Symbicort* US share performance



Emerging Markets: AstraZeneca continues to outpace the market in China



*MNC: multi national companies

Japan: Continued strong performance, *Nexium* #1 PPI in value



- 1Q Growth +13% CER
- In-market growth +15%
- Continued share growth for *Crestor*, *Symbicort* & *Nexium*
- *Forxiga* approved in March

1Q 2014: Pipeline update

Briggs Morrison, Executive Vice President Global Medicines Development

19 candidates for NME registration trial starts in 2014-15

We anticipate 4-5 NME Phase III starts in 2014

2014	2015	
AZD9291 NSCLC	**AZD4547** gastric cancer	**ATM AVI** serious infections
MEDI4736 solid tumours	**MEDI-573** metastatic breast cancer	**RDEA3170** gout
tralokinumab asthma	**MEDI-551** chronic lymphocytic leukaemia (CLL)	**sifalimumab/MEDI-546** systemic lupus erythematosus (SLE)
roxadustat (FG-4592) ESRD/CKD	**volitinib (AZD6094)** papillary renal cell carcinoma	**PT010** (LABA/LAMA/ICS) COPD
AZD3293 Alzheimer's disease	**AZD1775** ovarian cancer	**AZD5069** asthma
mavrilimumab rheumatoid arthritis (RA)	**MEDI3617** ovarian cancer	**AZD1722** end stage renal disease (ESRD)
	AZD9150 diffuse large B-cell lymphoma (DLBCL)	

2014: Continued momentum in late stage pipeline



2014: Continued momentum in late stage pipeline



AZD9291: Achieving FDA Breakthrough Designation

Best % change from baseline in target lesions, n=34



Source: Ransom M, et al. Data presented at a mini-oral session at the 15th World Conference of Lung Cancer, Sydney, Australia, 27-30 October 2013
Further data updates at ASCO, 2014.

1Q 2014: Continued momentum in late stage pipeline

Regulatory milestones

Compound	Indication	Milestone
Farxiga/Forxiga	type 2 diabetes	US, JP approval ✓
***Bydureon* Dual Chamber Pen**	type 2 diabetes	US approval ✓
Xigduo	type 2 diabetes	EU approval ✓
Myalept	generalised lipodystrophy	US approval ✓
olaparib	PSR BRCAm ovarian cancer	US filing, granted Priority Review ✓
AZD9291	2L T790m NSCLC*	US Breakthrough Therapy designation ✓

* Patients with metastatic, EGFR T790M mutation-positive, non-small cell lung cancer whose NSCLC has progressed during treatment with an FDA-approved, EGFR tyrosine kinase inhibitor.

2014: Key data readouts

Compound	Indication	Milestone
Quarter 2		
brodalumab	psoriasis	Ph III topline results
saxagliptin/dapagliflozin	type 2 diabetes	Ph III (ADA[1])
MEDI4736	solid tumours	Ph I (ASCO[2])
AZD9291	NSCLC	Ph I (ASCO[2])
Quarter 3		
lesinurad	gout	Ph III topline results
CAZ AVI	cIAI	Ph III topline results
sifalimumab/anifrolumab	SLE	Ph IIb topline results
oncology portfolio	various tumours	(ESMO[3])
AZD3293	Alzheimer's disease	Ph I (AAIC[4])
Quarter 4		
brodalumab	psoriasis	Ph III topline results
mavrilimumab	RA	Ph IIb (ACR[5])

[1]ADA in San Francisco, June 13-17, 2014, [2]ASCO in Chicago, May 30- June 3, 2014, [3]ESMO in Madrid, September 26-30, 2014,
[4]AAIC in Copenhagen, July 12-17, 2014, [5]ACR in Boston, November 14-19, 2014

2014: Regulatory milestones

Compound	Indication	Milestone
Quarter 2		
Epanova	hypertriglyceridaemia	US approval (PDUFA 5 May)
***Bydureon* Dual Chamber Pen**	type 2 diabetes	JP filing
Quarter 3		
Iressa	EGFRm NSCLC	US filing
naloxegol	OIC	US approval (PDUFA 16 Sep)
Brilinta	ACS	JP approval
Quarter 4		
olaparib	PSR BRCAm ovarian cancer	US approval (PDUFA 3 Oct)
Xigduo XR	type 2 diabetes	US approval
saxagliptin/dapagliflozin FDC	type 2 diabetes	US filing
***Bydureon* Dual Chamber Pen**	type 2 diabetes	CHMP opinion
Myalept	lipodystrophy	EU filing
lesinurad	gout	EU, US filing
CAZ AVI	cIAI	EU filing

2Q 2014: Data readouts at congresses

ATS – San Diego, May 16-20

- benralizumab (IL-5R) Ph II asthma and COPD
- tralokinumab (IL-13) Ph II asthma
- MEDI9929 (TSLP) Ph I asthma
- Analyst meeting: Tuesday May 20, 2014

ASCO – Chicago, May 30-June 3

- AZD9291 Ph I NSCLC
- MEDI4736 (PD-L1) Ph I monotherapy and early, preliminary tremelimumab (CTLA-4) combination
- cediranib + olaparib ovarian cancer
- Analyst meeting: Monday June 2, 2014

ADA – San Francisco, June 13-17

- saxagliptin + dapagliflozin Ph III T2D
- *Forxiga* long term efficacy and safety CV/HTN
- Sustained A1c control of exenatide vs insulin glargine and DURATION 1 extension data

RIA | Oncology | CVMD

Potential NME & LCM submissions 2014-16



* Filing is the responsibility of partner

1Q 2014: Financial performance

Marc Dunoyer, Chief Financial Officer

Headline results: 1Q 2014

	1Q 2014	1Q 2013	CER growth %
Revenue	6,416	6,385	3
Core Operating Profit	1,952	2,324	(11)
Core EPS	**$1.17**	**$1.41**	**(11)**

Revenue Fx impact -2.1% in 1Q



Core margin: 1Q 2014

	$m	CER growth %	% sales
Revenue	**6,416**	**3**	
Core Gross Margin	5,223	2	81.4
Distribution	(72)	(5)	1.1
Core SG&A	(2,317)	14	36.1
Core R&D	(1,098)	13	17.1
Core Other Income	216	29	3.3
Core Operating Profit	**1,952**	**(11)**	**30.4**

Core SG&A and R&D trends



Cash generation: 1Q 2014

	1Q 2014 $m	1Q 2013 $m
EBITDA	1,548	2,048
Movement in working capital	30	290
Tax & interest paid	(598)	(527)
Other non-cash movements	207	387
Net cash from operating activities	**1,187**	**2,198**

Cash application: 1Q 2014

	1Q 2014 $m
Net cash from operating activities	1,187
Net capex	(671)
Dividends/share issues	(2,228)
Acquisitions and business development	(3,068)
Other movements	(92)
Net cash flow after distributions	**(4,872)**

Guidance for 2014 (maintained)

2014 Revenue (CER)	Low-to-mid single digit decline
2014 Core EPS (CER)	Percentage decline in the teens
Dividend	Progressive dividend policy maintained

Above guidance assumes US *Nexium* generic end of May 2014

1Q 2014: Closing remarks

Pascal Soriot, Chief Executive Officer



Closing remarks

1Q revenue growth driven by all 5 growth platforms

Strong momentum in late stage Pipeline

Rich news flow expected in 2014



AstraZeneca
1Q 2014 Results